Survival Difference of Endometrial Cancer Patients with Peritoneal Metastasis Receiving Cytoreductive Surgery (CRS) with and without Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Systematic Review and Meta-Analysis
Abstract
1. Introduction
2. Materials and Methods
2.1. Search Strategy
2.2. Data Extraction
2.3. Statistical Analysis
3. Results
3.1. Studies Investigating the Effect of CRS plus HIPEC on the Survival of ECPM
3.2. Studies Investigating the Effect of CRS Only on the Survival of ECPM
3.3. Comparison of the Survival Differences between ECPM Patients Treated with CRS Only and CRS plus HIPEC
4. Discussion
4.1. Cellular and Molecular Effects of HIPEC
4.2. Clinical Effectiveness of CRS Only and CRS plus HIPEC in ECPM
4.2.1. Studies Investigating CRS Only
4.2.2. Studies Investigating CRS plus HIPEC
4.2.3. The Comparison of CRS-Only and CRS-plus-HIPEC Studies
4.3. Strengths and Limitations of the Meta-Analysis
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- Siegel, R.L.; Miller, K.D.; Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 2020, 70, 7–30. [Google Scholar] [CrossRef] [PubMed]
- Smrz, S.A.; Calo, C.; Fisher, J.L.; Salani, R. An ecological evaluation of the increasing incidence of endometrial cancer and the obesity epidemic. Am. J. Obstet. Gynecol. 2021, 224, 506.e1–e8. [Google Scholar] [CrossRef] [PubMed]
- Chen, L.-M.; Berek, J.S. Endometrial Carcinoma: Epidemiology, Risk Factors, and Prevention. Available online: https://www.uptodate.com/contents/endometrial-carcinoma-epidemiology-risk-factors-and-prevention (accessed on 2 May 2024).
- Bradford, L.S.; Rauh-Hain, J.A.; Schorge, J.; Birrer, M.J.; Dizon, D.S. Advances in the management of recurrent endometrial cancer. Am. J. Clin. Oncol. 2015, 38, 206–212. [Google Scholar] [CrossRef]
- Colombo, N.; Creutzberg, C.; Amant, F.; Bosse, T.; Gonzalez-Martin, A.; Ledermann, J.; Marth, C.; Nout, R.; Querleu, D.; Mirza, M.R.; et al. ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group. ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, treatment and follow-up. Ann. Oncol. 2016, 27, 16–41. [Google Scholar] [CrossRef] [PubMed]
- Gomes David, M.; Bakrin, N.; Salleron, J.; Kaminsky, M.C.; Bereder, J.M.; Tuech, J.J.; Lehmann, K.; Mehta, S.; Glehen, O.; Marchal, F. Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs. CRS alone for treatment of endometrial cancer with peritoneal metastases: A multi-institutional study from PSOGI and BIG RENAPE groups. BMC Surg. 2022, 22, 1. [Google Scholar] [CrossRef] [PubMed]
- Bakrin, N.; Cotte, E.; Sayag-Beaujard, A.; Raudrant, D.; Isaac, S.; Mohamed, F.; Gilly, F.N.; Glehen, O. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of recurrent endometrial carcinoma confined to the peritoneal cavity. Int. J. Gynecol. Cancer 2010, 20, 809–814. [Google Scholar] [CrossRef]
- Rauh-Hain, J.A.; Del Carmen, M.G. Treatment for advanced and recurrent endometrial carcinoma: Combined modalities. Oncologist 2010, 15, 852–861. [Google Scholar] [CrossRef]
- Minareci, Y.; Tosun, O.A.; Sozen, H.; Topuz, S.; Salihoglu, M.Y. A Retrospective Clinical Analysis of Hyperthermic Intraperitoneal Chemotherapy in Gynecological Cancers: Technical Details, Tolerability, and Efficacy. Medeni. Med. J. 2020, 35, 202–211. [Google Scholar] [CrossRef] [PubMed]
- Tempfer, C.B.; Kern, P.; Dogan, A.; Hilal, Z.; Rezniczek, G.A. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for endometrial cancer-derived peritoneal metastases: A systematic review. Clin. Exp. Metastasis 2019, 36, 321–329. [Google Scholar] [CrossRef]
- Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71. [Google Scholar] [CrossRef] [PubMed]
- Therneau, T.M.; Grambsch, P.M. Modeling Survival Data: Extending the Cox Model; Springer: New York, NY, USA, 2000. [Google Scholar]
- Wan, X.; Wang, W.; Liu, J.; Tong, T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med. Res. Methodol. 2014, 14, 135. [Google Scholar] [CrossRef] [PubMed]
- Luo, D.; Wan, X.; Liu, J.; Tong, T. Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Stat. Methods Med. Res. 2018, 27, 1785–1805. [Google Scholar] [CrossRef] [PubMed]
- Shi, J.; Luo, D.; Weng, H.; Zeng, X.T.; Lin, L.; Chu, H.; Tong, T. Optimally estimating the sample standard deviation from the five-number summary. Res. Synth. Methods 2020, 11, 641–654. [Google Scholar] [CrossRef] [PubMed]
- Shi, J.; Luo, D.; Wan, X.; Liu, Y.; Liu, J.; Bian, Z.; Tong, T. Detecting the skewness of data from the five-number summary and its application in meta-analysis. Stat. Methods Med. Res. 2023, 32, 1338–1360. [Google Scholar] [CrossRef] [PubMed]
- Balduzzi, S.; Rucker, G.; Schwarzer, G. How to perform a meta-analysis with R: A practical tutorial. Evid. Based Ment. Health 2019, 22, 153–160. [Google Scholar] [CrossRef] [PubMed]
- Harrer, M.; Cuijpers, P.; Furukawa, T.A.; Ebert, D.D. Doing Meta-Analysis With R: A Hands-on Guide, 1st ed.; Chapman & Hall/CRC Press: Boca Raton, FL, USA; London, UK, 2021. [Google Scholar]
- Viechtbauer, W. Bias and Efficiency of Meta-Analytic Variance Estimators in the Random-Effects Model. J. Educ. Behav. Stat. 2005, 30, 261–293. [Google Scholar] [CrossRef]
- Higgins, J.P.; Thompson, S.G. Quantifying heterogeneity in a meta-analysis. Stat. Med. 2002, 21, 1539–1558. [Google Scholar] [CrossRef]
- Egger, M.; Smith, G.D.; Schneider, M.; Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315, 629–634. [Google Scholar] [CrossRef]
- Mantel, N.; Haenszel, W. Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 1959, 22, 719–748. [Google Scholar]
- Robins, J.; Greenland, S.; Breslow, N.E. A general estimator for the variance of the Mantel-Haenszel odds ratio. Am. J. Epidemiol. 1986, 124, 719–723. [Google Scholar] [CrossRef] [PubMed]
- Helm, C.W.; Toler, C.R.; Martin, R.S., 3rd; Gordinier, M.E.; Parker, L.P.; Metzinger, D.S.; Edwards, R.P. Cytoreduction and intraperitoneal heated chemotherapy for the treatment of endometrial carcinoma recurrent within the peritoneal cavity. Int. J. Gynecol. Cancer 2007, 17, 204–209. [Google Scholar] [CrossRef] [PubMed]
- Delotte, J.; Desantis, M.; Frigenza, M.; Quaranta, D.; Bongain, A.; Benchimol, D.; Bereder, J.M. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of endometrial cancer with peritoneal carcinomatosis. Eur. J. Obstet. Gynecol. Reprod. Biol. 2014, 172, 111–114. [Google Scholar] [CrossRef] [PubMed]
- Abu-Zaid, A.; Azzam, A.Z.; AlOmar, O.; Salem, H.; Amin, T.; Al-Badawi, I.A. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for managing peritoneal carcinomatosis from endometrial carcinoma: A single-center experience of 6 cases. Ann. Saudi Med. 2014, 34, 159–166. [Google Scholar] [CrossRef] [PubMed]
- Cornali, T.; Sammartino, P.; Kopanakis, N.; Christopoulou, A.; Framarino Dei Malatesta, M.; Efstathiou, E.; Spagnoli, A.; Ciardi, A.; Biacchi, D.; Spiliotis, J. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Metastases from Endometrial Cancer. Ann. Surg. Oncol. 2018, 25, 679–687. [Google Scholar] [CrossRef] [PubMed]
- Brind’Amour, A.; Brault, C.; Sideris, L.; De Guerke, L.; Auclair, M.H.; Dube, P.; Fortin, S. Carboplatin Hyperthermic Intraperitoneal Chemotherapy in the Management of Primary Stage IVB Endometrial Cancer. J. Obstet. Gynaecol. Can. 2021, 43, 247–250. [Google Scholar] [CrossRef]
- Chambers, L.M.; Chau, D.; Yao, M.; Costales, A.B.; Rose, P.G.; Michener, C.M.; Debernardo, R.; Vargas, R. Efficacy of hyperthermic intraperitoneal chemotherapy and interval debulking surgery in women with advanced uterine serous carcinoma. Gynecol. Oncol. Rep. 2021, 38, 100876. [Google Scholar] [CrossRef] [PubMed]
- Rajha, A.; Piso, P.; Halmy, L.; Panczel, I.; Nedelcut, D.S.; Herold, Z.; Szasz, A.M.; Acs, M. Rare Histologies and Infrequent Indications for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Anticancer Res. 2022, 42, 3681–3692. [Google Scholar] [CrossRef] [PubMed]
- Navarro-Barrios, A.; Gil-Martinez, J.; Ramos-Bernardo, I.; Barrios, P.; Munoz-Casares, C.; Torres-Melero, J.; Pereira, F.; Manzanedo, I.; Arjona, A.; Martinez-Regueira, F.; et al. Intraperitoneal hyperthermic chemotherapy after cytoreduction in patients with peritoneal metastases from endometrial cancer. The next frontier? Surg. Oncol. 2020, 33, 19–23. [Google Scholar] [CrossRef]
- Chambers, L.M.; Jia, X.; Rose, P.G.; AlHilli, M. Impact of treatment modality on overall survival in women with advanced endometrial cancer: A National Cancer Database analysis. Gynecol. Oncol. 2021, 160, 405–412. [Google Scholar] [CrossRef]
- Chi, D.S.; Welshinger, M.; Venkatraman, E.S.; Barakat, R.R. The role of surgical cytoreduction in Stage IV endometrial carcinoma. Gynecol. Oncol. 1997, 67, 56–60. [Google Scholar] [CrossRef] [PubMed]
- Bristow, R.E.; Zerbe, M.J.; Rosenshein, N.B.; Grumbine, F.C.; Montz, F.J. Stage IVB endometrial carcinoma: The role of cytoreductive surgery and determinants of survival. Gynecol. Oncol. 2000, 78, 85–91. [Google Scholar] [CrossRef] [PubMed]
- Bristow, R.E.; Duska, L.R.; Montz, F.J. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. Gynecol. Oncol. 2001, 81, 92–99. [Google Scholar] [CrossRef] [PubMed]
- Ayhan, A.; Taskiran, C.; Celik, C.; Yuce, K.; Kucukali, T. The influence of cytoreductive surgery on survival and morbidity in stage IVB endometrial cancer. Int. J. Gynecol. Cancer 2002, 12, 448–453. [Google Scholar] [CrossRef]
- Sood, B.M.; Jones, J.; Gupta, S.; Khabele, D.; Guha, C.; Runowicz, C.; Goldberg, G.; Fields, A.; Anderson, P.; Vikram, B. Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2003, 57, 208–216. [Google Scholar] [CrossRef]
- Moller, K.A.; Gehrig, P.A.; Van Le, L.; Secord, A.A.; Schorge, J. The role of optimal debulking in advanced stage serous carcinoma of the uterus. Gynecol. Oncol. 2004, 94, 170–174. [Google Scholar] [CrossRef]
- van Wijk, F.H.; Huikeshoven, F.J.; Abdulkadir, L.; Ewing, P.C.; Burger, C.W. Stage III and IV endometrial cancer: A 20-year review of patients. Int. J. Gynecol. Cancer 2006, 16, 1648–1655. [Google Scholar] [CrossRef]
- Thomas, M.B.; Mariani, A.; Cliby, W.A.; Keeney, G.L.; Podratz, K.C.; Dowdy, S.C. Role of cytoreduction in stage III and IV uterine papillary serous carcinoma. Gynecol. Oncol. 2007, 107, 190–193. [Google Scholar] [CrossRef]
- Landrum, L.M.; Moore, K.N.; Myers, T.K.; Lanneau, G.S., Jr.; McMeekin, D.S.; Walker, J.L.; Gold, M.A. Stage IVB endometrial cancer: Does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis. Gynecol. Oncol. 2009, 112, 337–341. [Google Scholar] [CrossRef]
- Ueda, Y.; Enomoto, T.; Miyatake, T.; Egawa-Takata, T.; Ugaki, H.; Yoshino, K.; Fujita, M.; Kimura, T. Endometrial carcinoma with extra-abdominal metastasis: Improved prognosis following cytoreductive surgery. Ann. Surg. Oncol. 2010, 17, 1111–1117. [Google Scholar] [CrossRef]
- Patsavas, K.; Woessner, J.; Gielda, B.; Rotmensch, J.; Yordan, E.; Bitterman, P.; Guirguis, A. Optimal surgical debulking in uterine papillary serous carcinoma affects survival. Gynecol. Oncol. 2011, 121, 581–585. [Google Scholar] [CrossRef]
- Shih, K.K.; Yun, E.; Gardner, G.J.; Barakat, R.R.; Chi, D.S.; Leitao, M.M., Jr. Surgical cytoreduction in stage IV endometrioid endometrial carcinoma. Gynecol. Oncol. 2011, 122, 608–611. [Google Scholar] [CrossRef] [PubMed]
- Tanner, E.J.; Leitao, M.M., Jr.; Garg, K.; Chi, D.S.; Sonoda, Y.; Gardner, G.J.; Barakat, R.R.; Jewell, E.L. The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma. Gynecol. Oncol. 2011, 123, 548–552. [Google Scholar] [CrossRef]
- Eto, T.; Saito, T.; Kasamatsu, T.; Nakanishi, T.; Yokota, H.; Satoh, T.; Nogawa, T.; Yoshikawa, H.; Kamura, T.; Konishi, I. Clinicopathological prognostic factors and the role of cytoreduction in surgical stage IVb endometrial cancer: A retrospective multi-institutional analysis of 248 patients in Japan. Gynecol. Oncol. 2012, 127, 338–344. [Google Scholar] [CrossRef]
- Huang, C.Y.; Tang, Y.H.; Chiang, Y.C.; Wang, K.L.; Fu, H.C.; Ke, Y.M.; Lau, H.Y.; Hsu, K.F.; Wu, C.H.; Cheng, W.F. Impact of management on the prognosis of pure uterine papillary serous cancer—A Taiwanese Gynecologic Oncology Group (TGOG) study. Gynecol. Oncol. 2014, 133, 221–228. [Google Scholar] [CrossRef]
- Lee, L.J.; Demaria, R.; Berkowitz, R.; Matulonis, U.; Viswanathan, A.N. Clinical predictors of long-term survival for stage IVB uterine papillary serous carcinoma confined to the abdomen. Gynecol. Oncol. 2014, 132, 65–69. [Google Scholar] [CrossRef] [PubMed]
- Wilkinson-Ryan, I.; Frolova, A.I.; Liu, J.; Stewart Massad, L.; Thaker, P.H.; Powell, M.A.; Mutch, D.G.; Hagemann, A.R. Neoadjuvant chemotherapy versus primary cytoreductive surgery for stage IV uterine serous carcinoma. Int. J. Gynecol. Cancer 2015, 25, 63–68. [Google Scholar] [CrossRef]
- Cirik, D.A.; Karalok, A.; Ureyen, I.; Tasci, T.; Koc, S.; Turan, T.; Tulunay, G. Stage IVB endometrial cancer confined to the abdomen: Is chemotherapy superior to radiotherapy? Eur. J. Gynaecol. Oncol. 2016, 37, 226–231. [Google Scholar]
- Tai, Y.J.; Hsu, H.C.; Chiang, Y.C.; Chen, Y.L.; Chen, C.A.; Cheng, W.F. Impact of Adjuvant Modalities on Survival in Patients with Advanced Stage Endometrial Carcinoma: A Retrospective Analysis from a Tertiary Medical Center. Int. J. Environ. Res. Public. Health 2019, 16, 2561. [Google Scholar] [CrossRef] [PubMed]
- Kanno, M.; Yunokawa, M.; Kurihara, N.; Aoki, Y.; Omi, M.; Tanigawa, T.; Kanao, H. Efficacy of intra-abdominal cytoreductive surgery in advanced endometrial cancer with distant metastasis. J. Gynecol. Oncol. 2023, 34, e77. [Google Scholar] [CrossRef] [PubMed]
- Creutzberg, C.L.; van Putten, W.L.; Koper, P.C.; Lybeert, M.L.; Jobsen, J.J.; Warlam-Rodenhuis, C.C.; De Winter, K.A.; Lutgens, L.C.; van den Bergh, A.C.; van de Steen-Banasik, E.; et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: Multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 2000, 355, 1404–1411. [Google Scholar] [CrossRef] [PubMed]
- Keys, H.M.; Roberts, J.A.; Brunetto, V.L.; Zaino, R.J.; Spirtos, N.M.; Bloss, J.D.; Pearlman, A.; Maiman, M.A.; Bell, J.G. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: A Gynecologic Oncology Group study. Gynecol. Oncol. 2004, 92, 744–751. [Google Scholar] [CrossRef] [PubMed]
- Sugarbaker, P.H. Peritonectomy procedures. Surg. Oncol. Clin. N. Am. 2003, 12, 703–727. [Google Scholar] [CrossRef] [PubMed]
- Barlin, J.N.; Puri, I.; Bristow, R.E. Cytoreductive surgery for advanced or recurrent endometrial cancer: A meta-analysis. Gynecol. Oncol. 2010, 118, 14–18. [Google Scholar] [CrossRef] [PubMed]
- Helderman, R.; Loke, D.R.; Verhoeff, J.; Rodermond, H.M.; van Bochove, G.G.W.; Boon, M.; van Kesteren, S.; Garcia Vallejo, J.J.; Kok, H.P.; Tanis, P.J.; et al. The Temperature-Dependent Effectiveness of Platinum-Based Drugs Mitomycin-C and 5-FU during Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Colorectal Cancer Cell Lines. Cells 2020, 9, 1775. [Google Scholar] [CrossRef] [PubMed]
- Kong, X.X.; Jiang, S.; Liu, T.; Liu, G.F.; Dong, M. Paclitaxel increases sensitivity of SKOV3 cells to hyperthermia by inhibiting heat shock protein 27. Biomed. Pharmacother. 2020, 132, 110907. [Google Scholar] [CrossRef] [PubMed]
- Alberts, D.S.; Peng, Y.M.; Chen, H.S.; Moon, T.E.; Cetas, T.C.; Hoeschele, J.D. Therapeutic synergism of hyperthermia-cis-platinum in a mouse tumor model. J. Natl. Cancer Inst. 1980, 65, 455–461. [Google Scholar] [PubMed]
- Rietbroek, R.C.; van de Vaart, P.J.; Haveman, J.; Blommaert, F.A.; Geerdink, A.; Bakker, P.J.; Veenhof, C.H. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells. J Cancer Res Clin Oncol 1997, 123, 6–12. [Google Scholar] [CrossRef]
- Li, X.F.; Carlin, S.; Urano, M.; Russell, J.; Ling, C.C.; O’Donoghue, J.A. Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy. Cancer Res. 2007, 67, 7646–7653. [Google Scholar] [CrossRef]
- Su, B.C.; Chen, G.Y.; Yang, C.M.; Chuang, W.T.; Lin, M.C.; Hsu, P.L.; Lee, C.W.; Cheng, C.C.; Wu, S.Y.; Pan, B.S.; et al. Impacts of hyperthermic chemotherapeutic agent on cytotoxicity, chemoresistance-related proteins and PD-L1 expression in human gastric cancer cells. Int. J. Hyperth. 2024, 41, 2310017. [Google Scholar] [CrossRef]
- Zhang, X.L.; Shi, H.J.; Wang, J.P.; Tang, H.S.; Wu, Y.B.; Fang, Z.Y.; Cui, S.Z.; Wang, L.T. MicroRNA-218 is upregulated in gastric cancer after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and increases chemosensitivity to cisplatin. World J. Gastroenterol. 2014, 20, 11347–11355. [Google Scholar] [CrossRef] [PubMed]
- Patankar, S.; Tergas, A.I.; Wright, J.D. Comparative effectiveness research in gynecologic oncology. Cancer Treat. Res. 2015, 164, 237–259. [Google Scholar] [CrossRef] [PubMed]
- Dhanis, J.; Blake, D.; Rundle, S.; Pijnenborg, J.M.A.; Smits, A. Cytoreductive surgery in recurrent endometrial cancer: A new paradigm for surgical management? Surg. Oncol. 2022, 43, 101811. [Google Scholar] [CrossRef] [PubMed]
- Jacquet, P.; Sugarbaker, P.H. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat. Res. 1996, 82, 359–374. [Google Scholar] [CrossRef] [PubMed]
- Bhatt, A.; Glehen, O.; Zivanovic, O.; Brennan, D.; Nadeau, C.; Van Driel, W.; Bakrin, N. The 2022 PSOGI International Consensus on HIPEC Regimens for Peritoneal Malignancies: Epithelial Ovarian Cancer. Ann. Surg. Oncol. 2023, 30, 8115–8137. [Google Scholar] [CrossRef] [PubMed]
- Mirza, M.R.; Chase, D.M.; Slomovitz, B.M.; dePont Christensen, R.; Novak, Z.; Black, D.; Gilbert, L.; Sharma, S.; Valabrega, G.; Landrum, L.M.; et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N. Engl. J. Med. 2023, 388, 2145–2158. [Google Scholar] [CrossRef] [PubMed]
- Mahdi, H.; Chelariu-Raicu, A.; Slomovitz, B.M. Immunotherapy in endometrial cancer. Int. J. Gynecol. Cancer 2023, 33, 351–357. [Google Scholar] [CrossRef] [PubMed]
- Quenet, F.; Elias, D.; Roca, L.; Goere, D.; Ghouti, L.; Pocard, M.; Facy, O.; Arvieux, C.; Lorimier, G.; Pezet, D.; et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021, 22, 256–266. [Google Scholar] [CrossRef]
- Li, J.; Wang, A.R.; Chen, X.D.; Zhang, Y.X.; Pan, H.; Li, S.Q. Effect of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery on the prognosis of patients with colorectal cancer peritoneal metastasis: A systematic review and meta-analysis. World J. Surg. Oncol. 2022, 20, 200. [Google Scholar] [CrossRef]
- Zhang, G.; Zhu, Y.; Liu, C.; Chao, G.; Cui, R.; Zhang, Z. The prognosis impact of hyperthermic intraperitoneal chemotherapy (HIPEC) plus cytoreductive surgery (CRS) in advanced ovarian cancer: The meta-analysis. J. Ovarian Res. 2019, 12, 33. [Google Scholar] [CrossRef]
- Filis, P.; Mauri, D.; Markozannes, G.; Tolia, M.; Filis, N.; Tsilidis, K. Hyperthermic intraperitoneal chemotherapy (HIPEC) for the management of primary advanced and recurrent ovarian cancer: A systematic review and meta-analysis of randomized trials. ESMO Open 2022, 7, 100586. [Google Scholar] [CrossRef] [PubMed]
- Hu, J.; Wang, Z.; Wang, X.; Xie, S. Side-effects of hyperthermic intraperitoneal chemotherapy in patients with gastrointestinal cancers. PeerJ 2023, 11, e15277. [Google Scholar] [CrossRef] [PubMed]
- Morano, W.F.; Aggarwal, A.; Love, P.; Richard, S.D.; Esquivel, J.; Bowne, W.B. Intraperitoneal immunotherapy: Historical perspectives and modern therapy. Cancer Gene Ther. 2016, 23, 373–381. [Google Scholar] [CrossRef] [PubMed]
- Ornella, M.S.C.; Badrinath, N.; Kim, K.A.; Kim, J.H.; Cho, E.; Hwang, T.H.; Kim, J.J. Immunotherapy for Peritoneal Carcinomatosis: Challenges and Prospective Outcomes. Cancers 2023, 15, 2383. [Google Scholar] [CrossRef] [PubMed]
Author (Year) | Type of Study | Cases (n) | Age (Mean) | PCI (Mean ± SD) | CRS + HIPEC Time (Hours; Mean) | HIPEC Time (min) | HIPEC Temperature (°C) | Hospital Stay Length (Days; Mean ± SD) |
---|---|---|---|---|---|---|---|---|
Helm et al. (2007) [25] | rObs | 5 | 61 | – 1 | 9.8 | 90 | 43 | 12.6 ± NA |
Bakrin et al. (2010) [8] | rObs | 5 | 55 | 9.60 ± 5.18 | 5.5 | 90 | 42 | 26.0 ± 27.4 |
Delotte et al. (2013) [26] | rObs | 13 | 66.5 | 11.46 ± 5.93 | 5 | 60 | 43 | 13.4 ± 2.0 |
Abu-Zaid et al. (2014) [27] | rObs | 6 | 55.5 | 19.33 ± 6.28 | 9.5 | 90 | 42 | 32.8 ± 9.5 |
Cornali et al. (2018) [28] | rObs | 33 | 58 | 16.03 ± 10.67 | 6.25 | 60 | 43 | 18.6 ± 20.3 |
Navarro-Barrios et al. (2020) [32] | pObs | 43 | 65 | 12.71 ± 9.2 | 7 | 60 / 90 | 42 | 11.0 ± 1.9 |
Brind’Amour et al. (2020) [29] | CS | 3 | 59.7 | 15.00 ± 4.36 | 9.3 | 90 | 42 | 16.3 ± 7.4 |
Chambers et al. (2021) [30] | rObs | 7 | 64.5 | – 1 | 6.9 | 90 | 43 | 6.1 ± 3.7 |
Gomes David et al. (2022) [7] | rObs | 30 | 60.9 | 9.86 ± 3.66 | 6.1 | 60 / 90 | 43 | – 1 |
Rajha et al. (2022) [31] | CS | 7 | 53 | 7.86 ± 3.98 | 4.55 | 60 | 42 | 16.4 ± 2.8 |
Author (Year) | Type of Study | Cases (n) | Age (Mean) |
---|---|---|---|
Chi et al. (1997) [34] | rObs | 45 | 66.6 |
Bristow et al. (2000) [35] | rObs | 65 | 63.8 |
Bristow et al. (2001) [36] | rObs | 31 | 63.8 |
Ayhan et al. (2002) [37] | rObs | 37 | 61.2 |
Sood et al. (2003) [38] | rObs | 42 | 65.9 |
Moller et al. (2004) [39] | rObs | 52 | 67.1 |
van Wijk et al. (2006) [40] | rObs | 67 | 62.3 |
Thomas et al. (2007) [41] | rObs | 26 | 64.0 |
Landrum et al. (2009) [42] | rObs | 55 | 62.5 |
Ueda et al. (2010) [43] | rObs | 30 | 62.9 |
Patsavas et al. (2011) [44] | rObs | 26 | 66.9 |
Shih et al. (2011) [45] | rObs | 52 | 64.8 |
Tanner et al. (2011) [46] | rObs | 44 | 68.4 |
Eto et al. (2012) [47] | rObs | 248 | 59.0 |
Huang et al. (2014) [48] | rObs | 32 | 61.8 |
Lee et al. (2014) [49] | rObs | 48 | 70.0 |
Wilkinson-Ryan et al. (2015) [50] | rObs | 34 | 69.1 |
Cirik et al. (2016) [51] | rObs | 62 | 58.2 |
Tai et al. (2019) [52] | rObs | 40 | 54.9 |
Gomes David et al. (2022) [7] | rObs | 30 | 63.9 |
Kanno et al. (2023) [53] | rObs | 50 | 60.2 |
Parameter | All Studies | Studies Conducted after 2010 | ||
---|---|---|---|---|
CRS only | CRS + HIPEC | CRS only | CRS + HIPEC | |
1-year survival rate (95% CI) | 64.68% (57.42–71.94%) | 82.28% (70.99–93.57%) | 69.78% (66.07–73.48%) | 81.86% (69.58–94.15%) |
2-year survival rate (95% CI) | 36.95% (30.39–43.52%) | 56.07% (46.38–65.76%) | 43.15% (35.27–51.03%) | 54.05% (43.78–64.32%) |
5-year survival rate (95% CI) | 16.45% (11.74–21.17%) | 21.88% (10.40–33.35%) | 19.24% (12.12–26.36%) | 21.88% (10.40–33.35%) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Panczel, I.; Acs, M.; Herold, M.; Madar-Dank, V.; Piso, P.; Schlitt, H.J.; Dank, M.; Szasz, A.M.; Herold, Z. Survival Difference of Endometrial Cancer Patients with Peritoneal Metastasis Receiving Cytoreductive Surgery (CRS) with and without Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Systematic Review and Meta-Analysis. Int. J. Mol. Sci. 2024, 25, 7495. https://doi.org/10.3390/ijms25137495
Panczel I, Acs M, Herold M, Madar-Dank V, Piso P, Schlitt HJ, Dank M, Szasz AM, Herold Z. Survival Difference of Endometrial Cancer Patients with Peritoneal Metastasis Receiving Cytoreductive Surgery (CRS) with and without Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences. 2024; 25(13):7495. https://doi.org/10.3390/ijms25137495
Chicago/Turabian StylePanczel, Ivan, Miklos Acs, Magdolna Herold, Viktor Madar-Dank, Pompiliu Piso, Hans Jürgen Schlitt, Magdolna Dank, Attila Marcell Szasz, and Zoltan Herold. 2024. "Survival Difference of Endometrial Cancer Patients with Peritoneal Metastasis Receiving Cytoreductive Surgery (CRS) with and without Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Systematic Review and Meta-Analysis" International Journal of Molecular Sciences 25, no. 13: 7495. https://doi.org/10.3390/ijms25137495
APA StylePanczel, I., Acs, M., Herold, M., Madar-Dank, V., Piso, P., Schlitt, H. J., Dank, M., Szasz, A. M., & Herold, Z. (2024). Survival Difference of Endometrial Cancer Patients with Peritoneal Metastasis Receiving Cytoreductive Surgery (CRS) with and without Hyperthermic Intraperitoneal Chemotherapy (HIPEC): A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 25(13), 7495. https://doi.org/10.3390/ijms25137495